EU/3/06/384: Orphan designation for the treatment of pancreatic cancer

Human telomerase reverse transcriptase peptide (611-626) (tertomotide)

Table of contents


On 25 July 2006, orphan designation (EU/3/06/384) was granted by the European Commission to Pharmexa A/S, Denmark, for human telomerase reverse transcriptase peptide (611-626) for the treatment of pancreatic cancer (tertomotide).

This medicine is now known as tertomotide.

Key facts

Active substance
Human telomerase reverse transcriptase peptide (611-626) (tertomotide)
Intended use
Treatment of pancreatic cancer
Orphan designation status
EU designation number
Date of designation

Klifo A/S
Smedeland 36
2600 Glostrup Hovedstaden

Update history

May 2009The sponsorship was transferred to Gemvax A/S, Norway, in May 2009.
April 2020The sponsor’s address was updated in April 2020.
May 2020The sponsorship was transferred to Klifo A/S, Denmark.
August 2023Please note that this product was withdrawn from the Union Register of orphan medicinal products in August 2023 on request of the Sponsor.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating